Remix Therapeutics
https://www.remixtx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Remix Therapeutics
Roche's Partnership Playbook: A Closer Look At 2023's Successes And 2024's Prospects
After chasing late-stage assets in 2023, Roche is moving back to its more diverse dealmaking approach. The company’s global head of pharma partnering, James Sabry, spoke to In Vivo about the value of partnerships at Roche and the formula for a successful collaboration.
Finance Watch: Three New Funds Bring $1.6bn-Plus For Biopharma Firms Globally
Private Company Edition: TCGX raises $1bn for its second fund, Goldman Sachs’ first fund totals $650m and Panlin’s biopharma fund grows. Also, Apollo’s series C increases to $260m, Avistone closes a $140m series B, OnCusp raises a $100m series A and HI-Bio grabs $95m in series B cash.
Remix Teams Up With Second Big Pharma With Roche Deal For RNA Technology
The news comes just under two years after Remix signed a partnership with J&J, and the biotech announced the same-day closing of a $60m financing to develop its lead product candidate.
The Busiest Dealmakers Of 2022
With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice